At Amunix, we have developed a novel half-life extension technology based on XTEN, a hydrophilic, unstructured polypeptide which can be recombinantly fused or chemically conjugated to other peptides, proteins, and small molecules. We have applied our XTEN technology platform to targets in a wide range of therapeutic areas, creating new protein pharmaceuticals characterized by improved efficacy, safety, and dosing.

Amunix Announces Expansion to Licensing Agreement with Janssen for Its Proprietary XTEN Technology

Mountain View, CA – January 7, 2014 – Amunix Operating Inc. (Amunix) announced today that Janssen Biotech, Inc. (Janssen) has expanded its existing worldwide research collaboration and licensing agreement with Amunix, increasing the number of available options for potential products. Under the terms of the agreement, Amunix will combine its XTEN half-life technology with the additional therapeutic molecules selected by Janssen over the duration of the agreement. Janssen will be responsible for all preclinical and clinical development as well as for manufacturing and commercialization of all resulting products.

Preclinical Data from Biogen Idec-Amunix Partnership Presented at ISTH Congress

MOUNTAIN VIEW, CA - (Marketwired - July 1, 2013) - Amunix Operating Inc. (Amunix) announced that the first of five presentations made by Biogen Idec – featuring preclinical research from the company’s XTEN technology partnership – was presented today at the XXIV International Society on Thrombosis and Haemostasis (ISTH) Congress in Amsterdam. During the course of the meeting, Biogen Idec investigators will present data on novel coagulation factor compositions utilizing the proprietary XTEN technology developed at Amunix.